Please assess the completion status of the following clinical trial:

Trial Title: Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18 years of age or older~* Confirmed diagnosis of multiple myeloma(MM) by Durie and Dalmon staging criteria on IV bisphosphonate therapy with either pamidronate or zoledronic acid for 8-12 months~* MM patients in either CR (complete response) or PR (partial response) by EBMT criteria~* ECOG Performance Status of 0-2~Exclusion Criteria:~* MM patients on active anti-MM therapy (maintenance regimens allowed)~* Renal failure with serum creatinine \>2mg/dL and/or creatinine clearance of \<30ml/min~* Relapsed, refractory or progressive disease~* Any condition or situation that, in the opinion of the investigator, may put the subject at significant risk, confound the results of the study, or interfere significantly with the subject's participation in the study~* Hypersensitivity or any contraindication to a single dose of zoledronic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: OTHER): Single arm biomarker study after a single dose of zoledronic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).